Abstract
Platelet-activating factor (PAF) is a lipid mediator that has been implicated in a variety of keratinocyte functions. Keratinocytes express the specific receptor for PAF (PAF-R), a seven-transmembrane G-protein-coupled receptor. Although PAF-R-dependent stimulation of numerous signal transduction pathways has been shown in a variety of cell types, to date there has been no analysis of PAF-R signal transduction in human epidermal cells. There is also contradictory evidence that PAF acts as either a suppressor or activator of keratinocyte proliferation. Using a model system created by retroviral-mediated transduction of the PAF-R into the PAF-R-negative epidermal cell line KB, we now demonstrate that the activation of the epidermal PAF-R results in the activation of both the extracellular signal-regulated kinase (ERK) and p38, but not the jun N-terminal kinase mitogen-activated protein (MAP) kinase pathways. Additionally, we show that the activation of the PAF-R stimulates the replication of epidermal cells. The activation of the ERK signal transduction pathway, as well as the PAF-dependent increase in cell proliferation, was dependent on the transactivation of the epidermal growth factor receptor (EGF-R). PAF-R-induced transactivation of the EGF-R was blocked by pharmacologic inhibitors of matrix metalloproteinases, of heparin-binding epidermal growth factor (HB-EGF), and specific inhibitors of the EGF-R tyrosine kinase. Activation of p38 MAP kinase by the PAF-R was not dependent on EGF-R activation and represents a distinct pathway of PAF-R-mediated signal transduction. In summary, these studies provide a mechanism whereby the PAF-R can exert proliferative effects through the activation of the EGF-R.
Footnotes
-
↵1 These authors contributed equally to the work.
-
This research was supported in part by grants from the Showalter Memorial Foundation, and National Institute of Health Grants K08AR1993 and R01HL62996. M. M. was supported by Brazilian grants from the Fundcao de Amparo a Pesquisa do Estado de Sao Paulo.
- Abbreviations:
- PAF
- platelet-activating factor
- PAF-R
- PAF receptor
- CPAF
- 1-O-hexadecyl-2-N-methylcarbamoyl-glycerophosphocholine or carbamoyl PAF
- EGF-R
- epidermal growth factor receptor
- HB-EGF
- heparin-binding EGF
- DAPH
- 4,5-dianilinophthalimide
- GPCR
- G-protein-coupled receptor
- MMP
- matrix metalloproteinase
- MAP
- mitogen-activated protein
- ERK
- extracellular signal-regulated kinase
- JNK
- jun N-terminal kinase
- PI 3′K
- phosphatidylinositol 3-kinase
- PKC
- protein kinase C
- IL
- interleukin
- MTT
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- PD98059
- 2′-amino-3′-methoxyflavone
- WEB-2086
- morpholine,4-(3-(4-(2-chlorophenyl-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolol(4,3-a)(1,4)diazepin-2-yl)-1-oxopropyl
- LY294002
- 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
- AG 1478
- 4-(3-chloroanilino)-6,7-dimethoxyquinazoline
- GM6001
- N-(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-l-tryptophan methylamide
- CRM 197
- [Glu52]-diphtheria toxin
- Received September 28, 2001.
- Accepted November 30, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|